
|Articles|June 5, 2006
GPhA lauds FDA approval of Omnitrope
The Generic Pharmaceutical Association (GPhA) called the approvalof Sandoz Pharmaceutical's Omnitrope human growth hormone (HGH) asignificant first step in bringing more affordablebiopharmaceuticals to the U.S. marketplace. GPhA president/CEOKathleen Jaeger said that FDA's Omnitrope decision demonstratesthat sound science exists to support the approval of genericbiopharmaceuticals.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Committee Votes Unanimously to Recommend mRNA Flu Vaccine
2
How Will Emerging AI Impact the Pharmacy Benefit Manager Space?
3
McKesson Partners with Pharmacies to Grow, Navigate Challenges
4
Metformin Cuts Long COVID Risk by Half in New ACTIV-6 Trial Results
5





































